Results 81 to 90 of about 63,359 (335)

Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions.

Pharmacology and Therapeutics, 2022
To date, treatment options for patients with chemorefractory cholangiocarcinoma (CCA) are limited. However, the advancements in molecular techniques have recently increased the opportunity to offer molecularly targeted therapies to patients with several ...
D. Lavacchi, E. Caliman, G. Rossi, E. Buttitta, Cristina Botteri, S. Fancelli, E. Pellegrini, G. Roviello, S. Pillozzi, L. Antonuzzo   +9 more
semanticscholar   +1 more source

Mutant IDH1: An immunotherapeutic target in tumors [PDF]

OncoImmunology, 2014
The discovery of driver mutations in cancers has raised interest in their suitability as immunotherapeutic targets. A recent study demonstrates that a point mutation in isocitrate dehydrogenase 1 (IDH1R132H), expressed in gliomas and other tumors, is presented on human MHC class II and induces a mutation-specific CD4+ antitumor T cell response in ...
Theresa Schumacher, Wolfgang Wick, Michael Platten, Lukas Bunse   +3 more
openaire   +3 more sources

Sustained Clinical Response to Ivosidenib in Previously Treated Patients with Advanced Intrahepatic Cholangiocarcinoma Harboring an IDH1 R132 Mutation: Two Case Reports

Case Reports in Oncology
Introduction: Patients with progressing intrahepatic cholangiocarcinoma (iCCA) harboring an isocitrate dehydrogenase 1 (IDH1) mutation who received ivosidenib showed a median progression-free survival (PFS) benefit of 1.3 months compared to placebo in ...
Christian Müller, Sabine Franke, Timo Reisländer, Verena Keitel, Marino Venerito   +4 more
doaj   +1 more source

IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution

Cancer Medicine, 2020
Background Selective IDH1 and IDH2 inhibitors have been approved for targeted therapy of acute myeloid leukemia. Clinical trials for solid tumors with IDH1 and IDH2 (IDH1/2) mutations are ongoing.
Erika F. Rodriguez, Federico De Marchi, Parvez M. Lokhandwala, Deborah Belchis, Rena Xian, Christopher D. Gocke, James R. Eshleman, Peter Illei, Ming‐Tseh Li   +8 more
doaj   +1 more source

Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours. [PDF]

PLoS ONE, 2015
Glioblastoma can occur either de novo or by the transformation of a low grade tumour; the majority of which harbor a mutation in isocitrate dehydrogenase (IDH1). Anaplastic tumours are high-grade gliomas that may represent the final step in the evolution
Jason K Wasserman, Garth Nicholas, Rebecca Yaworski, Anne-Marie Wasserman, John M Woulfe, Gerard H Jansen, Santanu Chakraborty, Thanh B Nguyen   +7 more
doaj   +1 more source

IDH1/2 mutations in acute myeloid leukemia

Blood Research, 2022
The mutational and epigenetic landscape of acute myeloid leukemia (AML) has become increasingly well understood in recent years, informing on biological targets for precision medicine. Among the most notable findings was the recognition of mutational hot-
J. Byun, Seung-Joo Yoo, H. Kim, Jae-Sook Ahn, Y. Koh, J. Jang, S. Yoon   +6 more
semanticscholar   +1 more source

Therapeutic approach in glioblastoma multiforme with primitive neuroectodermal tumor components: case report and review of the literature [PDF]

, 2018
Glioblastoma multiforme (GBM) is the most common and aggressive malignant glioma that is treated with first-line therapy, using surgical resection followed by local radiotherapy and concomitant/adjuvant temozolomide (TMZ) treatment.
Berrios J. R. G., Bianco V., Caffarena G., Caporlingua A., Caporlingua F., Di Palma A., Fusto C., Magliocca F. M., Pecorari S., Prelaj A., Rebuzzi S. E., Salvati M., Tomao S.   +12 more
core   +1 more source

Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma

Scientific Reports, 2022
AbstractIDH1-mutated cholangiocarcinomas (CCAs) are an interesting group of neoplasia with particular behavior and therapeutic implications. The aim of the present work is to highlight the differences characterizing IDH1m and IDH1wt CCAs in terms of genomic landscape. 284 patients with iCCA treated for resectable, locally advanced or metastatic disease
Rimini, Margherita, Fabregat-Franco, Carles, Burgio, Valentina, Lonardi, Sara, Niger, Monica, Scartozzi, Mario, Rapposelli, Ilario Giovanni, Aprile, Giuseppe, Ratti, Francesca, Pedica, Federica, Verdaguer, Helena, Rizzato, Mario, Nichetti, Federico, Lai, Eleonora, Cappetta, Alessandro, Macarulla, Teresa, Fassan, Matteo, De Braud, Filippo, Pretta, Andrea, Simionato, Francesca, De Cobelli, Francesco, Aldrighetti, Luca, Fornaro, Lorenzo, Cascinu, Stefano, Casadei-Gardini, Andrea   +24 more
openaire   +6 more sources

DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML [PDF]

, 2014
<b>Background</b>. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are neoplastic disorders of hematopoietic stem cells. DNA methyltransferase inhibitors (DNMTi), 5-azacytidine (AzaC) and 5-aza-2’-deoxycytidine (Decitabine),
Adams, Peter, Clark, William, Cole, John, Copland, Mhairi, Edwards, John R., Lund, Kristin, McBryan, Tony, Pchelintsev, Nikolay A., VanderKraats, Nathan D.   +8 more
core   +2 more sources

IDH1 regulates the expression of interferon pathway-related gene IFIT3 [PDF]

Jichu yixue yu linchuang, 2021
Objective To explore the role of IDH1 in the expression of RNA binding proteins (RBPs) in glioma cell line LN229. Methods Lentivirus was used to construct IDH1 knockdown and control cells, and the expression of IDH1 was validated by RT-qPCR (real ...
TANG Wan-jun, PENG Xiao-zhong, HAN Wei
doaj